Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (11)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ihn, H.
Right arrow Articles by Tamaki, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ihn, H.
Right arrow Articles by Tamaki, K.
Related Collections
Right arrow Myositis and Muscle Disease
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 2002; 41: 1268-1272
© 2002 British Society for Rheumatology

Original Papers

Clinical significance of serum surfactant protein D (SP-D) in patients with polymyositis/dermatomyositis: correlation with interstitial lung disease

H. Ihn, Y. Asano, M. Kubo, K. Yamane, M. Jinnin, N. Yazawa, M. Fujimoto and K. Tamaki

Department of Dermatology, Faculty of Medicine, University of Tokyo, Tokyo, Japan

Objective. To determine the clinical significance of serum surfactant protein D (SP-D) levels in patients with polymyositis/dermatomyositis (PM/DM).

Methods. Serum SP-D levels were assayed using a sensitive enzyme-linked immunosorbent assay in 59 patients with PM/DM and in 29 healthy controls.

Results. The serum level of SP-D was significantly higher in patients with PM/DM than in healthy controls (mean±S.D. 61.7±122.6 vs 31.0±12.4 ng/ml, P < 0.01). The serum SP-D level in patients with interstitial lung disease (ILD) was significantly higher than in those without ILD (118.7±220.2 vs 38.7±21.0 ng/ml, P < 0.001). Serum level of SP-D was correlated with the presence of ILD. The incidences of decreased vital capacity (%VC) and of decreased diffusing capacity of carbon monoxidase (%DLCO) were also significantly greater in patients with an elevated SP-D level than in those with a normal level (64 vs 7%, P < 0.02; 73 vs 27%, P < 0.01). Moreover, the serum SP-D level was inversely correlated with %VC (r=-0.452, P < 0.01) and %DLCO (r=-0.349, P < 0.05).

Conclusion. The serum SP-D level may be a useful marker for ILD in patients with PM/DM.

KEY WORDS: Interstitial lung disease, Enzyme-linked immunosorbent assay, Vital capacity.

Correspondence to: H. Ihn, Department of Dermatology, Faculty of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113, Japan.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur Respir JHome page
K. M. Antoniou, G. Margaritopoulos, F. Economidou, and N. M. Siafakas
Pivotal clinical dilemmas in collagen vascular diseases associated with interstitial lung involvement
Eur. Respir. J., April 1, 2009; 33(4): 882 - 896.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
G. L. Sorensen, J. v. B. Hjelmborg, K. O. Kyvik, M. Fenger, A. Hoj, C. Bendixen, T. I. A. Sorensen, and U. Holmskov
Genetic and environmental influences of surfactant protein D serum levels
Am J Physiol Lung Cell Mol Physiol, May 1, 2006; 290(5): L1010 - L1017.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.